Business Wire

The NAGA Group announces challenger bank project NAGA Pay. NAGA China and NAGA Pro are launched, supported by strong April figures.

Share

The NAGA Group continues its high growth rate and announces new projects.

With NAGA Pay, NAGA will be launching its own challenger bank app, which for the first time combines mobile banking, trading, social trading and cryptocurrency trading.

"NAGA Pay is an ambitious project with great growth potential. In recent years we have gained a lot of experience in building a real-time trading platform with a clear monetization model across a wide range of asset classes. Our trading app and our cryptocurrency platform have processed millions of transactions. In parallel, our NAGA Card programme, which offers our customers a prepaid Mastercard and a European IBAN account, has shown very promising growth rates. We have also followed the projects in the multi-billion NEO-Banking / Challenger-Bank segment very closely and have created all the prerequisites to become part of this segment. Hence, we have decided to combine all our expertise in NAGA Pay and are currently developing a super app for mobile banking and investing. The entry into the payment vertical underlines the FinTech character of our company and will offer us new customer acquisition and growth opportunities without losing our focus on the core business", says Benjamin Bilski, founder and CEO of The NAGA Group AG.

NAGA Pay will be launched around the beginning of Q4 2020 as a separate native iOS- and Android app. The app combines the offer of a prepaid credit card, a European IBAN bank account with limits of up to € 200,000 per year and complete banking functions such as SEPA transfers. In addition to real-time money transfers and money management, NAGA customers can trade over 400 stocks from 9 global stock exchanges free of charge, as well as copy other top traders with one click. The offer is completed with the integration of the NAGA Wallet and NAGAX, so that customers can buy and sell physical cryptocurrencies with NAGA Pay and make blockchain-based deposits and withdrawals.

For more information and to register to the NAGA Pay waiting list https://www.naga.com/pay has been launched today.

Furthermore, NAGA is delighted to announce the launch of NAGA Pro. NAGA Pro is aimed specifically at users who already run their own financial trading community, are pursuing a career as a professional trader or want to build a business model in the trading space. NAGA-Pro offers its users a monthly base remuneration and a lucrative performance package if certain criteria are met, thereby creating a unique "digital influencer" model.

"NAGA Pro is a real growth catalyst for us. Due to the high level of investment in our own trading platform and our cooperation with 600,000 users and 1,500 partners, we understand the needs of users as well as professional traders, trainers and operators in the wider trading and investing world. We see this as a slight adjustment in our business model and positioning. Instead of plunging into the very expensive and "innovation-free" marketing battle for retail customers, we want to use our technology offer in a focused manner by helping entrepreneurs and businesses accelerate their growth and ultimately to grow together with us. In a nutshell, NAGA Pro is a tool for traders, professionals, and for all those with business models focused around trading who bring their community and followers with them or build up a community within NAGA. Thereby we will differentiate ourselves from the competition and expand our marketing and sales focus accordingly", commented Bilski.

The NAGA Pro model is already successfully practiced at NAGA. With pilot projects in Asia and Poland that started at the beginning of the year, over 30% of the total turnover can be attributed to the NAGA Pro pilots.

"Our unique selling point as the most innovative and user-friendly platform on the market is underpinned by NAGA Pro. The proof of concept has been delivered. We therefore see ourselves in the highly encouraging situation of being able to offer a "Platform-as-a-Service" or, as our NAGA Pro users say so nicely - "The Uber model for investing" - which is aimed at the operator and not only at the end user", adds Benjamin Bilski.

Further information on NAGA Pro can be found on the dedicated website naga.com/pro.

Finally, the company reports the preliminary results of April and the start of the project in China.

In April, NAGA achieved a strong revenue result of around € 2.2 million and a preliminary net profit of around € 0.6 million and therefore continued the strong growth and earnings momentum built in Q1 (Q1: revenues € 7.0 million, net profit €2.1m). In addition, a new record number of registrations was recorded in April, which can be seen as the foundation for further growth. NAGA is also delighted to report that the first transactions of the NAGA China project were processed during May, with management expecting further growth in the course of Q3 and especially Q4.

"We are fully dedicated to growth, we want to keep the momentum high and continue to show how much potential there is in NAGA's unique platform and our business model. Another focus of the next few months will be the optimization of acquisition costs, sustainable growth and, above all, the addition of new personnel, as we have just posted around 30 new vacancies," concludes Benjamin Bilski.

###

About NAGA

NAGA is an innovative fintech company that has developed a socially enhanced financial system that creates a unified and seamless experience across personal finance and investing. Its proprietary platform offers a range of products ranging from trading, investing, and cryptocurrencies to a physical Mastercard and social investing features such as a Feed, a Messenger and Auto-Copy. NAGA is a synergistic all-in-one solution that's accessible and inclusive, and that provides a better way to trade, invest, connect, earn, acquire and pay, across both fiat and crypto.

Language: English
Company: The NAGA Group AG
Hohe Bleichen 12
20354 Hamburg
Germany
E-mail: info@naga.com
Internet: www.naga.com
ISIN: DE000A161NR7
WKN: A161NR
Indices: Scale 30
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart, Tradegate Exchange

Contact information

Benjamin Bilski
Tel: +49 (0)40 5247 79153
Email: ben@naga.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 21:31:00 EESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the 25th European Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 15:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25th European Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leuke

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 14:57:00 EESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom